FDA warns of higher death risk with Pepaxto in multiple myelomaJuly 28, 2021Lymphoma & Plasma Cell Disorders
Real-world CAR T outcomes for DLBCL mimic clinical trialsJune 28, 2021DLBCLLymphoma & Plasma Cell Disorders
Experimental antibody-drug conjugate shown active against r/r DLBCLJune 15, 2021DLBCLLymphoma & Plasma Cell Disorders
Choosing the right R-CHOP dosage for elderly patients with DLBCLJune 8, 2021DLBCLLymphoma & Plasma Cell Disorders
High-dose methotrexate of no CNS benefit for patients with high-risk DLBCLMay 18, 2021DLBCLLymphoma & Plasma Cell Disorders
Pediatric cancer survivors at risk for opioid misuseMay 5, 2021Patient & Survivor CareOpioid Resource CenterPediatricsCNS/Brain CancerLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
No SPARKLE with ibrutinib plus chemo in r/r pediatric B-NHLMay 5, 2021Lymphoma & Plasma Cell Disorders
The power and promise of social media in oncologyMay 3, 2021Patient & Survivor CareBreast CancerCNS/Brain CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHead & Neck/Thyroid Cancers
Hyperprogression on immunotherapy: When outcomes are much worseApril 30, 2021ImmunotherapyNonmelanoma Skin CancerMelanomaBreast CancerGastroenterologyGastrointestinal CancerGenitourinary Cancer
FDA approves loncastuximab for diffuse large B-cell lymphomasApril 27, 2021Lymphoma & Plasma Cell Disorders
Frontline brentuximab vedotin shows promise in high-risk pediatric Hodgkin lymphomaApril 21, 2021Lymphoma & Plasma Cell DisordersPediatrics
Personalized cancer vaccine shows early promise across tumor typesApril 14, 2021Patient & Survivor CareBreast CancerGenitourinary CancerLymphoma & Plasma Cell DisordersHead & Neck/Thyroid CancersLung Cancer
Evidence favors lower-dose R-CHOP for fit, very elderly DLBCL patientsApril 14, 2021DLBCLLymphoma & Plasma Cell Disorders
